Interim report 2026
Filed with HKEX · Stock code 1228 · · 85 pages · English
Summary by 6ix AI
The report indicates a revenue increase attributed to sales growth from its products, Hunterase and Livmarli, despite a significant decrease in other income and gains. The company reported a loss for the reporting period, contrasting with a profit from the previous year, primarily due to reduced other income.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
CANbridge Pharmaceuticals Inc. on 6ix
Earlier from CANbridge Pharmaceuticals
- CANbridge Announces NHIA Reimbursement Approval of Livmarli for Alagille Syndrome and Progressive Familial Intrahepatic Cholestasis in Taiwan
- CANbridge Announces Strategic Partnership and Investment from Baheal to Strengthen Commercialization of Rare Disease Products
- CANbridge Pharmaceuticals Successfully Obtains Drug Manufacturing License Type B Certificate
- CANbridge Reports Positive Topline Data from CAN103 Pivotal Trial for Gaucher Disease in China, Plans NDA Filing in Q4 2024
- CANbridge Announces NDA Acceptance of CAN108 for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis by China's National Medical Products Administration
Later from CANbridge Pharmaceuticals
- Monthly return of equity issuer on movements in securities for the month ended 30 September 2026
- Monthly return of equity issuer on movements in securities for the month ended 31 October 2026
- Voluntary announcement - gaurunning and livmarli included in the first edition of commercial health insurance drug coverage cost table
Follow CANbridge Pharmaceuticals into a list and get an email when it puts out news.
Follow CANbridge Pharmaceuticals